Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
- Conditions
- CLL
- Interventions
- Registration Number
- NCT06073821
- Lead Sponsor
- BeiGene
- Brief Summary
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
- Detailed Description
Chronic lymphocytic leukemia is a type of blood cancer that affects people around the world. People with CLL suffer from enlarged lymph nodes, spleen, or liver, or have symptoms like night sweats, weight loss and fever. They have shorter life expectancy compared to healthy people. There is an urgent need for new treatment to prolong life and control disease-related symptoms.
In this study, participants with CLL without prior treatment will receive either venetoclax plus obinutuzumab combination treatment that is considered a standard first line treatment or receive sonrotoclax plus zanubrutinib. It is hypothesized that sonrotoclax plus zanubrutinib may be better than venetoclax plus obinutuzumab in treating CLL.
The main purpose of this study is to compare the duration the participants live without the CLL getting worse between participants who received sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab. Approximately 652 participants will be included in this study around the world. Participants will have equal chance to be allocated to receive either of the treatment combinations.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 652
- Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment
- Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2
- Measurable disease by Computer Tomography/Magnetic Resonance Imaging
- Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin < 3.0 x ULN
- Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute
- Previous systemic treatment for CLL
- Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
- Known central nervous system involvement
- History of confirmed progressive multifocal leukoencephalopathy (PML)
- Uncontrolled hypertension
Note: Other protocol defined criteria may apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sonrotoclax Plus Zanubrutinib Sonrotoclax Participants will receive from start of Cycle 1 a standard dose of zanubrutinib once or twice daily orally and in combination with sonrotoclax starting from Cycle 4 onwards at increasing doses until target dose is reached and continuing until end of Cycle 15 (each cycle is 28 days) Sonrotoclax Plus Zanubrutinib Zanubrutinib Participants will receive from start of Cycle 1 a standard dose of zanubrutinib once or twice daily orally and in combination with sonrotoclax starting from Cycle 4 onwards at increasing doses until target dose is reached and continuing until end of Cycle 15 (each cycle is 28 days) Venetoclax Plus Obinutuzumab Venetoclax Participants will receive obinutuzumab 100mg intravenously on Day 1 Cycle 1, followed by 900 mg on Day 2 Cycle 1 (or alternatively receive 1000 mg intravenously on Day 1), followed by 1000 mg on Days 8 and 15 of Cycle 1 and thereafter on Day 1 of Cycles 2 through 6 (each cycle is 28 days) in combination with venetoclax at increasing doses until target dose is reached from Day 22 Cycle 1 until end of Cycle 12 (each cycles is 28 days) Venetoclax Plus Obinutuzumab Obinutuzumab Participants will receive obinutuzumab 100mg intravenously on Day 1 Cycle 1, followed by 900 mg on Day 2 Cycle 1 (or alternatively receive 1000 mg intravenously on Day 1), followed by 1000 mg on Days 8 and 15 of Cycle 1 and thereafter on Day 1 of Cycles 2 through 6 (each cycle is 28 days) in combination with venetoclax at increasing doses until target dose is reached from Day 22 Cycle 1 until end of Cycle 12 (each cycles is 28 days)
- Primary Outcome Measures
Name Time Method Cohort 1: Progression Free Survival (PFS） Up to approximately 9 years PFS is defined as the time from the date of enrollment to the date of first confirmed disease progression or death due to any cause, whichever occurs first, as determined by independent review committee (IRC)
Cohort 1: Rate of Undetectable Measurable Residual Disease Up to one and a half years Undetectable measurable residual disease uMRD4 rate at the first Post- Treatment Follow-up (PTFU 1) Visit will be based on next-generation sequencing.
- Secondary Outcome Measures
Name Time Method Cohort 1: Complete Response Rate (CRR ) by IRC Up to approximately 9 years CRR is defined as the percentage of participants that achieved best response of complete response (CR)/ complete response with incomplete hematopoietic recovery (CRi), determined by IRC.
Cohort 1: Overall Survival (OS) Up to approximately 9 years OS is defined as time from the date of enrollment to the date of death because of any cause
Cohort 1: PFS by Investigator Assessment Up to approximately 9 years PFS is defined as the time from the date of enrollment to the date of first confirmed disease progression or death due to any cause, whichever occurs first, as determined by investigator assessment
Cohort 1: CRR by Investigator Assessment Up to approximately 9 years CRR is defined as the percentage of participants that achieved best response of complete response (CR)/ complete response with incomplete hematopoietic recovery (CRi), determined by Investigator Assessment
Cohort 1: Rate of Undetectable Measurable Residual Disease Up to approximately 9 years The overall uMRD4 rate is defined as the percentage of participants who achieve uMRD status in peripheral blood before disease progression or start of new anti-CLL treatment (whichever is earlier), based on flow cytometry.
Cohort 1: Overall Response Rate (ORR) by IRC and Investigator Assessment Up to approximately 9 years ORR is defined as the percentage of participants who achieve a response (CR, CRi, nodular partial remission (nPR), partial response (PR), and partial response with lymphocytosis \[PR-L\]), before disease progression or start of new anti-CLL treatment (whichever is earlier).
Cohort 1: Duration of Response (DOR) by IRC and Investigator Assessment Up to approximately 9 years DOR is defined as the time from first qualifying response PR, PR-L, CR, or CRi) until CLL progression or death.
Pooled Cohorts: PFS by IRC and Investigator Assessment Up to approximately 9 years PFS is defined as the time from the date of enrollment to the date of first confirmed disease progression or death due to any cause, whichever occurs first, as determined by IRC
Pooled Cohorts: ORR by IRC and Investigator Assessment Up to approximately 9 years ORR is defined as the percentage of participants who achieve a response (CR, CRi, nodular partial remission (nPR), partial response (PR), and partial response with lymphocytosis \[PR-L\]), before disease progression or start of new anti-CLL treatment （whichever is earlier）.
Pooled Cohorts: DOR by IRC and Investigator Assessment Up to approximately 9 years DOR is defined as the time from first qualifying response PR, PR-L, CR, or CRi) until CLL progression or death.
Pooled Cohorts: Rate of Undetectable Measurable Residual Disease Up to approximately 9 years The overall uMRD4 rate is defined as the percentage of participants who achieve uMRD status in peripheral blood before disease progression or start of new anti-CLL treatment (whichever is earlier),based on next-generation sequencing.
Pooled Cohorts: CRR by IRC and Investigator Assessment Up to approximately 9 years CRR is defined as the percentage of participants that achieved best response of complete response (CR)/ complete response with incomplete hematopoietic recovery (CRi), determined by Investigator Assessment
Cohort 1 and Pooled Cohorts: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Up to one and a half years for Sonrotoclax Plus Zanubrutinib group and 13 months for Venetoclax Plus Obinutuzumab group] Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Cohort 1 and Pooled Cohorts: Change from baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire -Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) and Physical Functioning Scales Every three cycles during the treatment period The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 =Not at all (best) to 4 =Very Much (worst) and 2 questions answered on a 7-point scale where 1 =Very poor (worst) to 7 =Excellent (best). Higher scores in GHS and functional scales indicate better quality of life.
Cohort 1 and Pooled Cohorts: Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales Every three cycles during the treatment period The symptom burden and physical condition/fatigue will be measured by EQ-5D-5L. EQ-5D-5L is a standardized instrument that measures health-related quality of life for men with prostate cancer. EQ-5D consists of EQ-5D descriptive system and EQ visual analogue scale (VAS). EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Number of participants with various responses to the mobility questionnaire are reported.
Cohort 1 and Pooled Cohorts: Change from baseline in European Quality of Life 5-Dimensions 5-Levels Health Questionnaire （EQ-5D-5L) Visual Analogue Scale (VAS). Every three cycles during the treatment period Mean change from baseline in EQ-5D-5L VAS. The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine. A higher score indicates better health outcomes.
Trial Locations
- Locations (210)
Alaska Oncology and Hematology, Llc
🇺🇸Anchorage, Alaska, United States
City of Hope National Medical Center
🇺🇸Duarte, California, United States
University of California San Diego (Ucsd) Moores Cancer Center
🇺🇸La Jolla, California, United States
Valkyrie Clinical Trials
🇺🇸Los Angeles, California, United States
UCLA Department of Medicine Hematologyoncology
🇺🇸Los Angeles, California, United States
Chao Family Comprehensive Cancer Center
🇺🇸Orange, California, United States
Stanford Medicine
🇺🇸Palo Alto, California, United States
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Medstar Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
Mount Sinai Comprehensive Cancer Center
🇺🇸Miami Beach, Florida, United States
Moffitt Cancer Center
🇺🇸Tampa, Florida, United States
Centricity Research Columbus Cancer Center
🇺🇸Columbus, Georgia, United States
Southeastern Regional Medical Center
🇺🇸Newnan, Georgia, United States
Chu Lille
🇫🇷Lille, France
Uniwersytecki Szpital Kliniczny
🇵🇱Poznan, Poland
Centralny Szpital Kliniczny Uck Wum
🇵🇱Warszawa, Poland
Northwestern University
🇺🇸Chicago, Illinois, United States
Illinois Cancercare, Pc
🇺🇸Peoria, Illinois, United States
Fort Wayne Medical Oncology and Hematology
🇺🇸Fort Wayne, Indiana, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Mission Cancer and Blood
🇺🇸Waukee, Iowa, United States
The University of Kansas Cancer Center
🇺🇸Westwood, Kansas, United States
Norton Cancer Institute Pavilion
🇺🇸Louisville, Kentucky, United States
Ochsner Clinic Foundation
🇺🇸New Orleans, Louisiana, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Pindara Private Hospital
🇦🇺Benowa, Queensland, Australia
John Theurer Cancer Center Hackensack University Medical Center
🇺🇸Hackensack, New Jersey, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health
🇺🇸New York, New York, United States
Columbia University Medical Center
🇺🇸New York, New York, United States
Clinical Research Alliance, Inc
🇺🇸Westbury, New York, United States
University of North Carolina At Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Atrium Health Levine Cancer Institute (Lci)
🇺🇸Charlotte, North Carolina, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Cleveland Clinic Foundation
🇺🇸Cleveland, Ohio, United States
The James Cancer Hospital and Solove Research Institute At Ohio State University
🇺🇸Columbus, Ohio, United States
Oncology Associates of Oregon Willamette Valley Cancer Center
🇺🇸Eugene, Oregon, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
Scri Tennessee Oncology Chattanooga
🇺🇸Chattanooga, Tennessee, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
Virginia Cancer Institute
🇺🇸Richmond, Virginia, United States
Vcu Health Systemmassey Comprehensive Cancer Center
🇺🇸Richmond, Virginia, United States
Fred Hutchinson Cancer Research Center
🇺🇸Seattle, Washington, United States
Gunderson Health System
🇺🇸La Crosse, Wisconsin, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
Genesiscare North Shore
🇦🇺St Leonards, New South Wales, Australia
Sunshine Coast Hospital and Health Service
🇦🇺Birtinya, Queensland, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Queensland, Australia
Flinders Medical Centre
🇦🇺Bedford PK, South Australia, Australia
Monash Health
🇦🇺Clayton, Victoria, Australia
St Vincents Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
Austin Health
🇦🇺Heidelberg, Victoria, Australia
Cabrini Hospital Malvern
🇦🇺Malvern East, Victoria, Australia
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Hollywood Private Hospital
🇦🇺Nedlands, Western Australia, Australia
Medizinische Universitatsklinik Innsbruck
🇦🇹Innsbruck, Austria
Universitatsklinik Fur Innere Medizin Iii Universitatsklinikum Der Pmu Landeskrankenhaus Salzburg
🇦🇹Salzburg, Austria
Hanusch Krankenhaus
🇦🇹Wien, Austria
Unesp Faculdade de Medicina Da Universidade Estadual Paulista Campus Botucatu
🇧🇷Botucatu, Brazil
Hospital Erasto Gaertner
🇧🇷Curitiba, Brazil
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
🇧🇷Porto Alegre, Brazil
Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp
🇧🇷Ribeirao Preto, Brazil
Hcfmusp Servico de Hematologia, Hemoterapia E Terapia Celular
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
🇧🇷Sao Paulo, Brazil
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
British Columbia Cancer Agency the Vancouver Centre
🇨🇦Vancouver, British Columbia, Canada
Cancercare Manitoba
🇨🇦Winnipeg, Manitoba, Canada
Lakeridge Health
🇨🇦Oshawa, Ontario, Canada
Princess Margaret Cancer Centre
🇨🇦Toronto, Ontario, Canada
Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
🇨🇦Greenfield Park, Quebec, Canada
Centre Hospitalier de Luniversite de Montreal (Chum)
🇨🇦Montreal, Quebec, Canada
Unite de Recherche Clinique Du Cisss Des Laurentides
🇨🇦SaintJerome, Quebec, Canada
Ciusss de Lestrie Chus
🇨🇦Sherbrooke, Quebec, Canada
Allan Blair Cancer Centre, Saskatchewan Cancer Agency
🇨🇦Regine, Saskatchewan, Canada
Saskatoon Cancer Centre
🇨🇦Saskatoon, Saskatchewan, Canada
Arthur Je Child Comprehensive Cancer Centre
🇨🇦Calgary, Canada
Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic)
🇨🇦Quebec, Canada
The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, Chongqing, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou, Fujian, China
Nanfang Hospital of Southern Medical University
🇨🇳Guangzhou, Guangdong, China
Jieyang Peoples Hospital (Jieyang Affiliated Hospital, Sun Yat Sen University )
🇨🇳Jieyang, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
🇨🇳Nanning, Guangxi, China
Nanyang Central Hospital
🇨🇳Nanyang, Henan, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
Yichang Central Peoples Hospitaljiangnan Branch
🇨🇳Yichang, Hubei, China
The First Peoples Hospital of Changzhou
🇨🇳Changzhou, Jiangsu, China
Jiangsu Province Hospital
🇨🇳Nanjing, Jiangsu, China
Affiliated Hospital of Nantong University
🇨🇳Nantong, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
🇨🇳Xuzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
The First Hospital of China Medical University
🇨🇳Shenyang, Liaoning, China
The Second Affiliated Hospital of Xian Jiaotong University
🇨🇳Xian, Shaanxi, China
Shandong Provincial Hospital
🇨🇳Jinan, Shandong, China
Jining No Peoples Hospital West Branch
🇨🇳Jining, Shandong, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, Shandong, China
West China Hospital, Sichuan University
🇨🇳Chengdu, Sichuan, China
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital
🇨🇳Chengdu, Sichuan, China
Institute of Hematology and Hospital of Blood Disease
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Fakultni Nemocnice Brno
🇨🇿Brno, Czechia
Fakultni Nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Fakultni Nemocnice Olomouc
🇨🇿Olomouc, Czechia
Fakultni Nemocnice Ostrava
🇨🇿Ostrava, Czechia
Fakultni Nemocnice Plzen
🇨🇿Plze, Czechia
Vseobecna Fakultni Nemocnice V Praze
🇨🇿Praha, Czechia
Centre de Lutte Contre Le Cancer Institut Bergonie
🇫🇷Bordeaux, France
Chu Clermont Ferrand Therapie Cellulaire and Hematolo
🇫🇷Clermontferrand, France
Clinique Louis Pasteur
🇫🇷Esseylesnancy, France
Centre Hospitalier Le Mans
🇫🇷Le Mans, France
Centre Leon Berard
🇫🇷Lyon Cedex, France
Centre Hospitalier Universitaire Nantes Hotel Dieu
🇫🇷Nantes, France
Hopital Prive Du Confluent
🇫🇷Nantes, France
Hopital de La Pitie Salpetriere
🇫🇷Paris, France
Chu Rennes
🇫🇷Rennes Cedes, France
Centre Henri Becquerel
🇫🇷Rouen Cedex, France
Chu Tours Hopital Bretonneau
🇫🇷Tours, France
Chu Nancy Hopital Brabois
🇫🇷VandoeuvrelesNancy, France
Praxis Am Volkspark
🇩🇪Berlin, Germany
Centrum Fur Haematologie Und Onkologie Bethanien
🇩🇪Frankfurt am Main, Germany
Universitaetsklinikum Schleswig Holstein Campus Luebeck
🇩🇪Luebeck, Germany
Assuta Ashdod Medical Center
🇮🇱Ashdod, Israel
Carmel Medical Center
🇮🇱Haifa, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Hadassah University Hospital Ein Kerem
🇮🇱Jerusalem, Israel
Assuta Medical Center
🇮🇱Tel Aviv Jaffa, Israel
Azienda Ospedaliera Universitaria Policlinico Santorsola Malpighi
🇮🇹Bologna, Italy
Azienda Ospedaliero Universitaria Di Ferrara
🇮🇹Ferrara, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Aou Maggiore Della Carita
🇮🇹Novara, Italy
Azienda Ospedaliera Di Padova
🇮🇹Padova, Italy
Ospedale Santa Maria Della Misericordia
🇮🇹Perugia, Italy
Aichi Cancer Center Hospital Clinical Oncology
🇯🇵Nagoya, Aichi, Japan
Chiba Cancer Center
🇯🇵Chibashi, Chiba, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Chiba, Japan
Nho Shikoku Cancer Center
🇯🇵MatsuyamaShi, Ehime, Japan
Aiiku Hospital
🇯🇵SapporoShi, Hokkaido, Japan
Hyogo Prefectural Amagasaki General Medical Center
🇯🇵AmagasakiCity, Hyogo, Japan
Kagoshima University Hospital
🇯🇵Kagoshimashi, Kagoshima, Japan
Tokai University Hospital
🇯🇵Iseharashi, Kanagawa, Japan
Tohoku University Hospital
🇯🇵Sendaishi, Miyagi, Japan
Niigata University Medical and Dental Hospital
🇯🇵Niigatashi, Niigata, Japan
Kurashiki Central Hospital
🇯🇵Kurashikishi, Okayama, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Osaka, Japan
Kindai University Hospital
🇯🇵Osakasayama, Osaka, Japan
National Cancer Center Hospital
🇯🇵ChuoKu, Tokyo, Japan
Yamagata University Hospital
🇯🇵Yamagatashi, Yamagata, Japan
Aomori Prefectural Central Hospital
🇯🇵Aomori, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
National Hospital Organization Okayama Medical Center
🇯🇵Okayama, Japan
Osaka Metropolitan University Hospital
🇯🇵Osaka, Japan
Yokohama Municipal Citizens Hospital
🇯🇵YokohamaShi, Japan
Seoul National University Bundang Hospital
🇰🇷BundangGu SeongnamSi, Gyeonggi-do, Korea, Republic of
National Cancer Center (Korea)
🇰🇷IlsandongGu GoyangSi, Gyeonggi-do, Korea, Republic of
The Catholic University of Korea, Seoul St Marys Hospital
🇰🇷SeochoGu, Seoul Teugbyeolsi, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷SeodaemunGu, Seoul Teugbyeolsi, Korea, Republic of
Seoul National University Hospital
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Asan Medical Center
🇰🇷SongpaGu, Seoul Teugbyeolsi, Korea, Republic of
Noordwest Ziekenhuisgroep
🇳🇱Alkmaar, Netherlands
Flevoziekenhuis
🇳🇱Almere, Netherlands
Meander Medisch Centrum
🇳🇱Amersfoort, Netherlands
Amsterdam Umc Vu Mc
🇳🇱Amsterdam, Netherlands
Reinier de Graaf Gasthuis
🇳🇱Delft, Netherlands
Albert Schweitzer Ziekenhuis
🇳🇱Dordrecht, Netherlands
Martini Ziekenhuis
🇳🇱Groningen, Netherlands
Maasstad Hospital
🇳🇱Rotterdam, Netherlands
Ikazia Ziekenhuis
🇳🇱Rotterdam, Netherlands
Franciscus Gasthuis and Vlietland
🇳🇱Schiedam, Netherlands
Hagaziekenhuis
🇳🇱Sgravenhage, Netherlands
Elisabeth Tweesteden Ziekenhuis
🇳🇱Tilburg, Netherlands
North Shore Hospital
🇳🇿Auckland, New Zealand
Auckland City Hospital
🇳🇿Auckland, New Zealand
Health New Zealand Canterbury
🇳🇿Christchurch, New Zealand
Dunedin Hospital
🇳🇿Dunedin, New Zealand
Tauranga Hospital
🇳🇿Tauranga, New Zealand
Wellington Regional Hospital (Ccdhb)
🇳🇿Wellington, New Zealand
Uniwersytecki Szpital Kliniczny Nr W Lublinie
🇵🇱Lublin, Poland
Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
🇵🇱OD, Poland
Instytut Hematologii I Transfuzjologii
🇵🇱Warszawa, Poland
Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
🇵🇱Wrocaw, Poland
Auxilio Mutuo Cancer Center
🇵🇷San Juan, Puerto Rico
Hospital Universitario de Burgos
🇪🇸Burgos, Spain
Institut Catala Doncologia Hospital Duran I Reynals
🇪🇸Hospitalet de LLobregat, Spain
Hospital Universitario de Gran Canaria Dr Negrin
🇪🇸Las Palmas Gran Canarias, Spain
Md Anderson Cancer Center Madrid Spain
🇪🇸Madrid, Spain
Hospital Universitario de Octubre
🇪🇸Madrid, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario Ramon Y Cajal
🇪🇸Madrid, Spain
Hospital La Candelaria
🇪🇸Tenerife, Spain
Karolinska Universitetssjukhuset Solna
🇸🇪Stockholm, Sweden
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
Gazi University
🇹🇷Ankara, Turkey
Erciyes University School of Medicine
🇹🇷Kayseri, Turkey
Kocaeli Universitesi Tip Fakultesi
🇹🇷Kocaeli, Turkey
University Hospitals Dorset Royal Bournemouth Hospital
🇬🇧Bournemouth, United Kingdom
Kent and Canterbury Hospital
🇬🇧Canterbury, United Kingdom
Churchill Hospital Oxford University Hospital Nhs Trust
🇬🇧Headington, United Kingdom
St Jamess University Hospital
🇬🇧Leeds, United Kingdom
The Clatterbridge Cancer Centre Liverpool
🇬🇧Liverpool, United Kingdom
University College Hospital
🇬🇧London, United Kingdom
Kings College
🇬🇧London, United Kingdom
Norfolk and Norwich University Hospitals Nhs Foundation Trust
🇬🇧Norwich, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom
Royal Marsden Nhs Foundation Royal Marsden Hospital
🇬🇧Sutton, United Kingdom